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Abstract
Background: Asymptomatic hypoglycemia in neonates may contribute to neurologic deficits during development. Whole-
blood glucose sensors are often imprecise and inaccurate at the low glucose concentrations found in neonates.
Subjects and Methods: In this study, a glucose sensor using a mutated glucose dehydrogenase that does not cross-react
significantly with maltose was evaluated at three pediatric centers. Blood samples (n = 575) from infants less than 30 days of
age (hematocrit 23–70%) were analyzed using six reagent lots on three ACCU-CHEK meters (Roche Diagnostics, In-
dianapolis, IN): the Inform II, Performa, and Aviva. Reference glucose level was determined in duplicate in perchloric acid
extracts using a coupled hexokinase procedure.
Results: Imprecision of glucose measurement using stable control materials ranged from 2.0% to 3.1% (coefficient of varia-
tion) using the glucose meters and from 0.8% to 5.3% (coefficient of variation) in perchloric acid–treated controls. The
difference between meter glucose values and reference values showed a slight dependence on hematocrit from 23% to 70%
(r = - 0.391, P< 0.001) but not in the typical range of neonatal hematocrit from 45% to 70% (r= - 0.036, P = 0.239). Linear
regression of the aggregated results yielded the following relationship: Meter glucose = 0.99 ·Reference Glucose+ 0.04;
r2 = 0.976; Syx = 0.249. Receiver-operator characteristic analysis of the data using 2.2mmol/L as the reference threshold for
hypoglycemia yielded an area under the curve value of 0.993. All infants with a glucose level of < 2.2mmol/L were detected
(100% sensitivity) when the meter glucose value was below 2.8mmol/L.
Conclusions: These data indicate that the modified ACCU-CHEK chemistry may be used effectively in neonatal settings to
detect clinically significant hypoglycemia.
Introduction
Point-of-care glucose meters are principally used todetect and prevent hyperglycemia in physicians’ office
laboratories, in acute care settings, and at home, work, or
school. Through the use of immobilized enzymes such as
glucose oxidase or glucose dehydrogenase, test strip chemis-
tries generate electrically active intermediates to determine
whole-blood glucose concentrations, which are typically
converted to a plasma equivalent value.1 Newer generations
of glucose meters require very small volumes (<1.0 lL) of
blood obtained from capillary puncture and provide results in
as little as 1min. Despite their simplicity and convenience,
point-of-care glucose meter technology is less accurate and
precise than enzymatic (primarily hexokinase) methods used
in automated central chemistry laboratories.2 Glucose meter
chemistry is also subject to a unique set of confounders that
include variations in hematocrit and tissue perfusion. For
these reasons, glucose meters are not recommended for use in
establishing a diagnosis of diabetes.
The purpose of the current study was to assess the capacity
of a whole-blood glucose monitor to detect clinically signifi-
cant hypoglycemia in newborns. The requirement for small
blood volumes and rapid testing makes whole glucose meters
particularly attractive in screening nursery populations
for hypoglycemia. However, newborns pose unique chal-
lenges for whole-blood glucose measurement. First, infant
hematocrits are higher (55–65%) than those in normal adult
males (40–50%) or females (35–45%), necessitating accurate
correction for differences in sample water content. Second,
postpartum hypoglycemia is relatively common as infants
transfer from transplacental to oral nutrition, and glucose
meter imprecision is greatest at these low glucose concentra-
tions. Third, newborns with plasma glucose concentrations
of £ 40mg/dL may be clinically asymptomatic, but such
concentrations have been associated with abnormalities of
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brain electrical activity and later neurocognitive deficits.3,4
Thus, quick recognition and correction of hypoglycemia are
essential to mitigate neurologic ramifications.
The Roche Diagnostics (Indianapolis, IN) ACCU-CHEK
blood glucose chemistry strip utilizes a bacterial glucose de-
hydrogenase belonging to a group of quinoprotein oxido-
reductases that use pyrroloquinolone quinone as the cofactor
rather than flavin or nicotinamide. The amount of current
generated by glucose oxidation is proportional to the blood
glucose concentration. The test strips in this study used a
mutant glucose dehydrogenase that did not display signifi-
cant reactivity to maltose (4-O-a-d-glucopyranosyl-d-glu-
cose),5,6 a component of some parenteral immunoglobulin
preparations and peritoneal dialysates. Reduced maltose re-
activity mitigates the potential overestimation of blood glu-
cose values in patients with increased circulating maltose that
may lead to inappropriate insulin administration.7 Over-
estimation of the glucose level due to an increased blood ga-
lactose level, however, remains a possibility,5 necessitating
cautious application in newbornswith signs and symptoms of
galactosemia. In the present study, this modified ACCU-
CHEK chemistry was challenged in three distinct neonatal
settings to detect clinically relevant hypoglycemia.
Materials and Methods
Analytical
All analytic procedures were carried out by certified med-
ical laboratory technologists. Three lots of test strips for each
of the meter systems were provided to each site by Roche
Diagnostics: Site 1 (ACCU-CHEK Performa) and Site 2
(ACCU-CHEK Inform II) used the same three strip lots, and
Site 3 (ACCU-CHEK Aviva) used three distinct strip lots.
Thus, in total, six strip lots were used in the study. Instrument
integrity and imprecision of each meter were monitored daily
at two concentrations. The order of sample application to the
glucose meters was varied every 10 specimens. Spun hemat-
ocrit was determined using a Readacrit microcentrifuge
system (Becton-Dickinson, Franklin Lakes, NJ) in singlicate
for each specimen. Reference glucose was determined using a
modified hexokinase/glucose-6-phosphate dehydrogenase
procedure at a central location on perchloric acid (PCA) ex-
tracts of whole blood prepared at each site. PCA extracts were
prepared by adding 50lL of whole blood to 500 lL of 0.33M
PCA (in duplicate) within 10min of glucose meter analysis
(mean, 2min). PCA-treated specimens were mixed and
centrifuged at 10,000 g for 10min to generate the whole-
blood extract. Plasma equivalent results were derived from
whole-blood glucose values by multiplying the perchlorate
results by the ratio of plasma water content to whole-blood
water content. Using values of plasma and red blood cell
water content of 0.93 kg/L and 0.71 kg/L, respectively,
whole-blood water content was calculated according the
following equation: (hematocrit)(0.71 kg/L) + (1 – hematocrit)
(0.93 kg/L).1
Patient samples and hospital settings
Site 1 (Performa) was an academic tertiary-care children’s
hospital with an associated nursery located in St. Louis, MO.
Samples at this site were derived from infants ranging in age
from 1 to 30 days (average, 4.2 days) in both the nursery and
the neonatal intensive care unit. Site 2 (Inform II) was a large
multispecialty medical center with an associated labor and de-
livery service located in SanDiego, CA. Samples at this sitewere
derived fromhealthy nursery infants ranging in age from 1 to 11
days (average, 1.2 days). Site 3 (Aviva) was a large urban hos-
pital for women and newborns located in Ogden, UT. Samples
at this site were derived from infants in the neonatal intensive
care unit ranging in age from 1 to 29 days (average, 10.5 days).
At each site a remnant aliquot of whole blood not exceeding
0.2mL was used for meter glucose determination, hematocrit
measurement, and PCA extraction. The protocol was approved
by the institutional review boards at each respective clinical site.
Statistical analyses
Descriptive statistics and linear least squares regression
were performed using Excel 2007 (Microsoft, Redmond
WA). Receiver-operator characteristic (ROC) analysis was
performed using SPSS version 20 (IBM, Armonk NY).
Results
Imprecision of glucose measurements
At the beginning and end of each testing day and at the
beginning and end of each strip vial, two levels of ACCU-
CHEK control were analyzed on each of the three study in-
struments at the three study sites. On each day that whole
blood PCA extracts were shipped for reference glucose de-
termination, three levels of stable control material (NERL
Diagnostics, East Providence, RI) were also extracted with
PCA and submitted along with the patient samples for ref-
erence glucose determination. Imprecision (coefficient of
variation) of meter glucose analysis ranged from 2.7% to 3.1%
at 2.5mmol/L and 2.0% to 2.4% at 16.8mmol/L across all
three sites (n= 209–395). Imprecision (coefficient of variation)
of the reference glucose level ranged from 1.4% to 3.4%, 1.2%
to 5.3%, and 1.0% to 4.4%, respectively, at concentrations of
2.8, 11.1, and 22.2mmol/L across all sites (n= 36–128). Site-
specific data are displayed in Table 1.
Table 1. Imprecision of Glucose Determination





(mmol/L) CV (%) n
Performa (Site 1) 2.5 2.7 209
17.0 2.0 209
Inform II (Site 2) 2.4 2.8 269
17.0 2.0 269
Aviva (Site 3) 2.4 3.1 395
16.7 2.4 395
PCA-hexokinase
Site 1 2.9 1.9 48
11.5 3.0 48
22.8 0.8 48
Site 2 2.8 1.4 36
11.3 1.2 36
22.5 3.4 36
Site 3 2.9 3.4 106
11.7 5.3 87
22.7 4.4 128
CV, coefficient of variation; PCA, perchloric acid.
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Sample characteristics at each site
The hematocrit values, glucose concentrations, and abso-
lute differences between meter and plasma at each site are
shown in Table 2. In general, hematocrit, glucose, and bias
were normally distributed at each site. The range of glucose
concentrations was similar at Sites 1 and 3 but slightly nar-
rower at Site 2. The range of hematocrit valueswas broadest at
Site 1, whereas higher hematocrits were overrepresented at
Site 2, and samples from Site 3 tended to have lower hemat-
ocrit values. Although similar across all three sites, the mean
bias at Site 2 was slightly higher than the other two sites,
reflecting a significant number of spuriously elevated meter
results. Amajority of themost elevatedmeter results ([meter –
plasma] > 0.5mmol/L) appeared to be due to sample specific
factors as these occurred across multiple strip lots. A small
fraction of the elevated results occurred in only one of the
triplicate determinations, suggesting a strip-specific or oper-
ator-dependent mechanism.
Accuracy of meter glucose determination
The derived plasma glucose values across all sites ranged
from 0.62 to 8.46mmol/L. These results from whole-blood
perchlorate extracts were compared with meter results from
all three sites using linear least-squares regression (Fig. 1). The
regression equation of this relationship was as follows:
ACCU-CHEK glucose=0.99·Reference Glucose+0.04 (r=0.976,
Syx= 0.249). Bland–Altman analysis (Fig. 2) showed an average
bias of 0.03mmol/L (range, - 0.80 to 1.76mmol/L) across the
range of observed glucose concentrations. The average per-
centage bias was 1.15% (range, - 21.8% to 58.1%). Bias did
not vary significantly with glucose concentration (r= 0.006,
P= 0.81). Meter results exceeded ISO 151978 accuracy criteria
across the range of concentrations observed. Of the 1,161meter
results, 1,158 (99.7%) were within 0.83mmol/L (15mg/dL) of
the reference glucose value in samples with glucose concen-
trations £ 4.17mmol/L (75mg/dL). Of 552 results from spec-
imens with glucose concentrations > 4.17mmol/L, 549 (99.5%)
were within 20% of the reference glucose. Meter results also
met accuracy guidelines in CLSI POCT 12-A3.9 For samples
with glucose concentrations > 5.56mmol/L (100mg/dL), 72
(96%) of 75 meter results were within 12.5% of the reference
value. For samples with glucose concentrations £ 5.56mmol/
L, > 98% of the 1,638 meter results were within 0.67mmol/L
(12mg/dL) and 20% of the reference glucose value.
Table 2. Specimen and Meter Performance







Number of samples 201 157 213
Glucose (mmol/L)
Average 3.80 3.38 3.90
Median 3.70 3.43 4.09
Range 0.64–8.34 1.60–5.75 0.98–8.74
Hematocrit (%)
Average 50 53 41
Median 49 54 41
Range 24–68 39–70 23–58
Bias (mmol/L)
Average - 0.03 0.08 - 0.01
Median - 0.02 0.11 0.00
Range - 0.77 to 0.77 - 0.8 to 1.76 -0.53 to 0.56
FIG. 1. Comparison plot of meter glucose values versus derived plasma glucose values. All data derived from the Performa
(B), Inform II (7), and Aviva (,) meters are shown.
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Influence of hematocrit on meter
glucose concentrations
Sample hematocrit varied from 23% to 70% across all
clinical sites. Bias between the derived plasma glucose level
and the meter concentration was significantly correlated with
hematocrit (r= - 0.391, P < 0.001). Although the correlation
was statistically significant, the slope of this relationship
wasmodest (0.01mmol/L decrease in glucose per 1% increase
in hematocrit). Visual examination of the data (Fig. 3) indi-
cated that the magnitude of the meter bias was greatest at
hematocrits below 35%. In the range of hematocrit most
commonly observed in the first neonatal week (45–70%), bias
and hematocrit were not significantly correlated (r= - 0.036,
P = 0.239).
Clinical performance
ROC analysis was performed to characterize the diagnostic
accuracy of each meter system in detecting hypoglycemia
(<2.2mmol/L). The areas under the ROC curve for the Per-
forma, Inform II, andAviva systems (95% confidence interval)
were 0.999 (0.997–1.00), 0.986 (0.979–0.993), and 0.999 (0.997–
1.00), respectively. Across all platforms, a meter cutoff of
FIG. 2. Bias of meter glucose versus plasma glucose across observed range of glucose concentrations: (upper panel)
absolute difference of (meter glucose – plasma glucose) versus glucose concentration and (lower panel) percentage difference
between meter and plasma glucose as a function of glucose concentration. All data derived from the Performa (B), Inform II
(7), and Aviva (,) meters are shown.
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2.8mmol/L detected all cases of hypoglycemia with a speci-
ficity of 99%.
Discussion
The performance of bedside glucose measurement has
come under much recent scrutiny, in large part because of
tight glycemic control programs in critically ill adults.10–13 In
this study, we scrutinize the electrochemical detection of
glucose in whole blood using a variant of glucose dehydro-
genase with reduced maltose cross-reactivity in the detection
of neonatal hypoglycemia. Neonates pose a particularly sig-
nificant challenge to accurate bedside glucose measurement
because hematocrits vary widely and glucose concentrations
are routinely lower than those in adults. The stakes are high
in this population as prompt recognition and treatment of
neonatal hypoglycemia rely heavily on accurate glucose de-
termination as asymptomatic hypoglycemia can lead to per-
manent neurologic impairment.
Although the slope and intercept of meter glucose versus
plasma values indicate appropriate calibration, bias in indi-
vidual specimens varied routinely by – 20%. This variability
may derive from imprecision of the analytic system, operator-
dependent factors (e.g., under-/overdosing, timing), patient-
specific variables (e.g., matrix effects), or environmental
factors (e.g., temperature, humidity, altitude). In this dataset,
the impact of the operator is small as analyseswere conducted
by certified laboratory technologists. As a result, imprecision
of the glucosemeters was on parwithmany central laboratory
methods using stable control solutions. Table 2 indicates a
FIG. 3. Bias of meter glucose versus plasma glucose across range of observed hematocrit values: (upper panel) absolute
difference of (meter glucose – plasma glucose) versus hematocrit and (lower panel) percentage difference between meter
glucose and plasma glucose as a function of hematocrit. All data derived from the Performa (B), Inform II (7), and Aviva
(,) meters are shown.
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similar range of bias without respect to geography or patient
population, so the source of the variable meter bias thus re-
mains unclear.
Despite the observed bias, whole-blood glucose concen-
trations were clinically consistent with plasma values
even at concentrations of < 3mmol/L, where historical
performance of near-patient glucose monitors has been
poor. Area under the ROC curve for detecting glucose less
than 2.2mmol/L approached 1.0, and meter glucose values
were generally robust when challenged with an extreme
range of hematocrit. At lower hematocrits typical of acutely
ill infants, the apparent glucose level increased only
slightly with decreasing hematocrit. In the range of he-
matocrit typical of healthier newborns, glucose was not
affected by hematocrit. Collectively, these data indicate
that by using a conservative cutoff concentration such as
2.8mmol/L, the ACCU-CHEK blood glucose meter accu-
rately detects plasma glucose concentration < 2.2mmol/L
in neonates.
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